Circulating Factors in Nephrotic Syndrome

NCT ID: NCT06315504

Last Updated: 2024-03-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

104 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-04-01

Study Completion Date

2034-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective observational study to investigate the treatment-associated changes of circulating factors associated with glomerular diseases among patients with de novo nephrotic syndrome admitted to hospital for a kidney biopsy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nephrotic Syndrome Membranous Nephropathy Minimal Change Disease Primary Focal Segmental Glomerulosclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with de novo nephrotic syndrome

Observation

Intervention Type OTHER

Observation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Observation

Observation

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Plasma albumin \< 36 g/L
* Urine protein \>3.5 g/day or urine protein/creatinine-ratio (UPCR) \> 3.5 or urine albumin/creatinine-ratio (UACR) \>2200 mg/g
* Planned kidney biopsy
* Able to give written informed consent

Exclusion Criteria

* Kidney transplant recipient
* Previously undergone a kidney biopsy
* Unable to understand written information in Danish
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Iain Bressendorff

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Iain Bressendorff

MD PhD

Responsibility Role SPONSOR_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Iain Bressendorff, MD PhD

Role: CONTACT

+4524277139

Ditte Hansen, MD PhD

Role: CONTACT

+4538682056

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Nephrotic Syndrome Cohort

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Kidney Disease Biomarkers
NCT00255398 COMPLETED
Contrast Nephropathy Associated FFA
NCT06418542 ACTIVE_NOT_RECRUITING PHASE4
ADPKD Cohort Study
NCT02084849 COMPLETED